Table 2.
NNRTI susceptibility of recombinant HIV-1 subtype B and C containing mutations at codon 138 in RT.
| Virus | RPV | ETR | NVP | EFV | ||||
|---|---|---|---|---|---|---|---|---|
| EC50 (nM) | Fold-Ra (p-value)b | EC50 (nM) | Fold-R (p- value)a | EC50 (nM) | Fold-R (p-value)a | EC50 (nM) | Fold-R (p- value)a | |
| Subtype B | ||||||||
| WT | 0.3±0.1 | - | 1.3±0.2 | - | 280±10 | - | 2.5±0.9 | - |
| E138A | 1.5±0.2 | 5.6 (0.03) | 2.9±0.5 | 2.2 (0.05) | 230±9 | 0.8 (>0.05) | 1.3±0.5 | 0.5 (>0.05) |
| E138G | 0.7±0.4 | 2.5 (0.05) | 3.2±0.2 | 2.5 (0.05) | 360±9 | 1.3 (>0.05) | 1.3±0.4 | 0.2 (0.05) |
| E138K | 0.8±0.2 | 3.0 (0.04) | 2.8±0.3 | 2.2 (0.05) | 120±6 | 0.4 (>0.05) | 1.2±0.4 | 0.5 (0.03) |
| E138Q | 1.3±0.1 | 4.8 (0.04) | 4.0±0.1 | 3.1 (0.01) | 840±40 | 3.0 (0.05) | 2.6±0.3 | 1.0 (>0.05) |
| E138R | 1.6±0.4 | 6.0 (0.05) | 5.3±1.6 | 4.1 (0.04) | 490±140 | 1.8 (>0.05) | 3.2±0.4 | 1.3 (>0.05) |
| Subtype C | ||||||||
| WT | 2.2±0.6 | - | 0.7±0.3 | - | 75±15 | - | 0.6±0.1 | - |
| E138A | 7.3±1.4 | 3.3 (0.03) | 2.0±0.4 | 2.9 (0.01) | 90±20 | 1.2 (>0.05) | 0.9±0.1 | 1.5 (0.03) |
| E138G | 6.5±1.9 | 3.0 (0.03) | 1.9±0.4 | 2.7 (0.01) | 140±10 | 1.9 (0.02) | 0.8±0.3 | 1.3 (>0.05) |
| E138K | 11.8±3.6 | 5.4 (0.05) | 3.9±0.7 | 5.8 (0.002) | 170±20 | 2.3 (0.03) | 2.1±0.4 | 3.6 (0.01) |
| E138Q | 12.5±4.8 | 5.7 (0.05) | 3.4±1.6 | 5.0 (0.02) | 530±10 | 7.1 (0.01) | 2.7±0.4 | 4.6 (0.008) |
| E138R | 10.4±3.5 | 4.8 (0.03) | 4.7±1.3 | 6.8 (0.02) | 320±44 | 4.2 (0.04) | 1.9±0.4 | 3.3 (0.01) |
a
Fold-resistance = EC50Mutant/EC50WT for both subtype B and C HIV-1.
b
A p-value was calculated to determine whether the fold-change in EC50 between the WT and mutant viruses for each subtype, were statistically significant. This value was determined as follows: the concentrations of drug required to inhibit viral replication by 50% (EC50) from 3–6 independent experiments were log10 transformed and compared for statistically significant differences (p-value < 0.05) using the two-sample Student’s paired t test. The p-value